Pathologists tend to reclassify prior nonmalignant diagnoses

August 17, 2012
Pathologists tend to reclassify prior nonmalignant diagnoses
For dermatopathologists there is a trend toward reclassification of prior nonmalignant diagnoses of severely atypical dysplastic nevi as malignant, according to a study published in the September issue of the Journal of the American Academy of Dermatology.

(HealthDay) -- For dermatopathologists there is a trend toward reclassification of prior nonmalignant diagnoses of severely atypical dysplastic nevi as malignant, according to a study published in the September issue of the Journal of the American Academy of Dermatology.

Jason E. Frangos, M.D., from Harvard Medical School in Boston, and colleagues had a group of nine dermatopathologists review retrieved files and reevaluate 29 cases of dysplastic nevi with severe atypia and 11 cases of thin radial growth-phase melanoma, originally diagnosed in 1988 through 1990.

The researchers found the mean number of melanoma diagnoses in the revaluation to be 18, an increase from the 11 original diagnoses of melanoma. In all 11 cases, a majority agreed with the original melanoma diagnosis. In four of the 29 cases originally reported as dysplastic nevus with severe atypia, a majority of current raters diagnosed melanoma. Interrater agreement over time was excellent for cases originally diagnosed as melanoma (kappa, 0.88), and fair for cases originally diagnosed as severely atypical dysplastic nevus (kappa, 0.47).

"The results of this study provide support for the hypothesis that dermatopathologists are more likely to diagnose thin superficial spreading in biopsy specimens that were reported as dysplastic nevi with severe atypia in the past, e.g., some 20 years ago," the authors write.

Explore further: Risk of second primary melanoma up in pediatric patients

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Risk of second primary melanoma up in pediatric patients

June 28, 2012
(HealthDay) -- Pediatric patients diagnosed with an invasive cutaneous melanoma have nearly double the relative risk of developing a subsequent primary melanoma, compared with adults, according to a study published online ...

Accuracy of melanoma detection up in specialized clinics

June 21, 2012
(HealthDay) -- From 1998 to 2007, the accuracy of melanoma detection improved in specialized but not non-specialized clinical settings, according to research published in the July issue of the Journal of the American Academy ...

Recommended for you

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

New immunotherapy approach boosts body's ability to destroy cancer cells

January 12, 2018
Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes ...

Cancer's gene-determined 'immune landscape' dictates progression of prostate tumors

January 12, 2018
The field of immunotherapy - the harnessing of patients' own immune systems to fend off cancer - is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of ...

FDA approves first drug for tumors tied to breast cancer genes

January 12, 2018
(HealthDay)—The U.S. Food and Drug Administration on Friday approved the first drug aimed at treating metastatic breast cancers linked to the BRCA gene mutation.

Breast cancer gene does not boost risk of death: study

January 12, 2018
Young women with the BRCA gene mutation that prompted actress Angelina Jolie's pre-emptive and much-publicised double mastectomy are not more likely to die after a breast cancer diagnosis, scientists said Friday.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.